academic article

• The degree of intratumor mutational heterogeneity varies by primary tumor sub-site..  Oncotarget.  7:27185-27198. 2016
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker..  British journal of cancer.  101:1044-1050. 2009